Sign in

You're signed outSign in or to get full access.

Ye Chen

Research Analyst at HC Wainwright

Yi Chen is Managing Director and Senior Healthcare Analyst at H.C. Wainwright & Co., specializing in equity research focused on biotechnology and pharmaceutical companies. He actively covers over 76 publicly traded healthcare firms including notable names such as Alpha Tau Medical, VERU, and DRTS, and holds a career success rate of approximately 43% with an average analyst return of 10.5%, as ranked by multiple research platforms. Dr. Chen began his analyst career in 2011 at Morgan Joseph TriArtisan LLC, advanced to Associate Director at Aegis Capital, and became Managing Director at H.C. Wainwright in 2015. He holds a Ph.D. in Biochemistry, is a CFA charterholder, and maintains FINRA licenses including Series 7, 63, 87, and 24.

Ye Chen's questions to OCULAR THERAPEUTIX (OCUL) leadership

Question · Q3 2025

Ye Chen inquired about the expected timeline for completing enrollment of 432 patients in the Helios 2 trial and whether NPDR patients might be difficult to enroll due to their potential reluctance to seek treatment.

Answer

Pravin U. Dugel, Executive Chairman, President and CEO, stated that the company anticipates no issues in efficiently completing enrollment for Helios 2, with the process already underway. He explained that significant demand and enthusiasm exist from sites and patients for a sustainable, single-injection treatment for advanced severe NPDR, mitigating concerns about patient reluctance.

Ask follow-up questions

Fintool

Fintool can predict OCULAR THERAPEUTIX logo OCUL's earnings beat/miss a week before the call